World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.

Find out what it is and see how you can get in with just a few dollars.

Preetam Shah Biography and Net Worth

CFO of Cidara Therapeutics

Founder of Saisarva LLC, Preetam Shah presently is Chief Financial & Business Officer at Cidara Therapeutics, Inc.

In the past Dr. Shah was Vice President-U.S. Operations & Investments at Reliance Capital Usa Ventures LLC, Chief Financial Officer, Treasurer & Executive VP of Brainstorm Cell Therapeutics, Inc., Director-Healthcare Investment Banking at Barclays Capital, Inc., Director-Healthcare Investment Banking at Lordes Capital Ltd. and Vice President-Healthcare Investment Banking at Canaccord Genuity, Inc.

Preetam Shah received an MBA from The Wharton School of the University of Pennsylvania and a doctorate from the University of Mississippi Medical Center.

What is Preetam Shah's net worth?: The estimated net worth of Preetam Shah is at least $145,905.57 as of March 11th, 2024. Dr. Shah owns 11,360 shares of Cidara Therapeutics stock worth more than $145,906 as of April 25th. This net worth evaluation does not reflect any other assets that Dr. Shah may own. Additionally, Dr. Shah receives an annual salary of $577,850.00 as CFO at Cidara Therapeutics. Learn More about Preetam Shah's net worth.
How old is Preetam Shah?: Dr. Shah is currently 51 years old. There are 5 older executives and no younger executives at Cidara Therapeutics. The oldest executive at Cidara Therapeutics is Dr. Jeffrey L. Stein Ph.D., President, CEO & Executive Director, who is 69 years old. Learn More on Preetam Shah's age.
What is Preetam Shah's salary?: As the CFO of Cidara Therapeutics, Inc., Dr. Shah earns $577,850.00 per year. There are 3 executives that earn more than Dr. Shah. The highest earning executive at Cidara Therapeutics is Dr. Jeffrey L. Stein Ph.D., President, CEO & Executive Director, who commands a salary of $873,250.00 per year. Learn More on Preetam Shah's salary.
How do I contact Preetam Shah?: The corporate mailing address for Dr. Shah and other Cidara Therapeutics executives is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. Cidara Therapeutics can also be reached via phone at (858) 752-6170 and via email at [email protected]. Learn More on Preetam Shah's contact information.
Has Preetam Shah been buying or selling shares of Cidara Therapeutics?: Preetam Shah has not been actively trading shares of Cidara Therapeutics within the last three months. Most recently, Preetam Shah sold 946 shares of the business's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $13.40, for a transaction totalling $12,676.40. Following the completion of the sale, the chief financial officer now directly owns 11,360 shares of the company's stock, valued at $152,224. Learn More on Preetam Shah's trading history.
Who are Cidara Therapeutics' active insiders?: Cidara Therapeutics' insider roster includes Neil Abdollahian (Insider), Paul Daruwala (COO), Timothy Franson (Director), Brady Johnson (VP), Jessica Oien (General Counsel), Preetam Shah (CFO), Jeffrey Stein (CEO), and Leslie Tari (Insider). Learn More on Cidara Therapeutics' active insiders.
Are insiders buying or selling shares of Cidara Therapeutics?: In the last twelve months, Cidara Therapeutics insiders bought shares 2 times. They purchased a total of 3,000 shares worth more than $57,700.00. In the last twelve months, insiders at the biotechnology company sold shares 4 times. They sold a total of 3,943 shares worth more than $58,005.00. The most recent insider tranaction occured on March, 11th when insider Leslie Tari sold 1,051 shares worth more than $14,083.40. Insiders at Cidara Therapeutics own 7.4% of the company. Learn More about insider trades at Cidara Therapeutics.
Information on this page was last updated on 3/11/2024.

Preetam Shah Insider Trading History at Cidara Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/11/2024	Sell	946	$13.40	$12,676.40	11,360
3/13/2023	Sell	332	$30.60	$10,159.20	7,407
9/19/2022	Sell	782	$15.40	$12,042.80	7,539
11/12/2021	Buy	1,000	$30.80	$30,800.00

Preetam Shah Buying and Selling Activity at Cidara Therapeutics

Cidara Therapeutics Company Overview

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Today's Range

Now: $12.84

$12.56

$14.96

50 Day Range

MA: $15.40

$10.25

$23.20

2 Week Range

Now: $12.84

$10.00

$29.60

Volume

554,367 shs

Average Volume

45,245 shs

Market Capitalization

$1.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98

Mysterious Gold Leverage Just Announced

From Stansberry Research | Ad

Find out what it is and see how you can get in with just a few dollars.

Preetam Shah Biography and Net Worth

What is Preetam Shah's net worth?

How old is Preetam Shah?

What is Preetam Shah's salary?

How do I contact Preetam Shah?

Has Preetam Shah been buying or selling shares of Cidara Therapeutics?

Who are Cidara Therapeutics' active insiders?

Are insiders buying or selling shares of Cidara Therapeutics?